Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 1.00 |
| ▸ | CA9 | Q16790 | 2/20 | 1.00 |
| ▸ | F11 | P03951 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | DAO | P14920 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.50 |
| ▸ | DDO | Q99489 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436560 | 0.85 | CA12 (0.74) | CA12CA9F11MAPTDAO | |
| SCHEMBL16573987 | 0.85 | CA12 (0.73) | CA12CA9F11MAPTDAO | |
| SCHEMBL13680545 | 0.81 | CA12 (0.67) | CA12CA9F11MAPTCA1 | |
| SCHEMBL6031111 | 0.77 | CA12 (0.62) | CA12CA9F11MAPTCA1 | |
| SCHEMBL2947571 | 0.77 | CA12 (0.62) | CA12CA9F11MAPTDAO | |
| SCHEMBL15345000 | 0.76 | CA12 (0.59) | CA12CA9F11MAPTCA1 | |
| SCHEMBL607156 | 0.75 | CA12 (0.60) | CA12CA9F11DAOCA1 | |
| SCHEMBL11461336 | 0.75 | CA12 (0.60) | CA12CA9MAPTDAOPIN1 | |
| SCHEMBL3368797 | 0.75 | CA12 (0.60) | CA12CA9F11CA1CA3 | |
| SCHEMBL14279696 | 0.75 | CA12 (0.60) | CA12CA9F11MAPTCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111850631-A | High-gloss decorative rhodium-plated layer electroplating solution | 金川集团股份有限公司 | 2020-10-30 | — | — | CN | claimed |
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | claimed |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | claimed |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-12 | — | — | US | claimed |
| EP-2190434-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2010-06-02 | — | — | EP | claimed |
| WO-2009024542-A2 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-26 | — | — | WO | claimed |
| US-20260068882-A1 | ARTHROPOD CONTROLLING COMPOSITION | FIRMENICH & CIE (CH) | 2026-03-12 | — | — | US | disclosed |
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| CN-113905612-B | Arthropod control composition | 弗门尼舍有限公司 | 2025-04-08 | — | — | CN | disclosed |
| US-20240374583-A1 | USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-11-14 | — | — | US | disclosed |
| US-12109209-B2 | Use of morphinan derivatives for treatment of opioid delta receptor agonist-related disease | NIPPON CHEMIPHAR CO., LTD. (JP) | 2024-10-08 | — | — | US | disclosed |
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT PASTEUR DE LILLE (FR) | 2024-10-03 | — | — | US | disclosed |
| US-12102631-B2 | Quinolylnitrones for the treatment and prevention of a cerebral stroke or ischaemia | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2024-10-01 | — | — | US | disclosed |
| US-5217977-A | Lipoxygenase inhibitor for treating diseases medicated by leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-08 | — | — | US | disclosed |
| US-5196419-A | Lipoxygenase enzyme inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-03-23 | — | — | US | disclosed |
| US-5134148-A | Heterocycles for use as inhibitors of leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-28 | — | — | US | disclosed |
| US-5112837-A | Inhibitors of thymidylate synthetase enzyme | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-05-12 | — | — | US | disclosed |
| EP-0385662-A2 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385663-A2 | Heterocyclic cycloalkanes as inhibitors of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0385679-A2 | Heterocyclic cyclic ethers with inhibitory activity on 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102631-B2 | Quinolylnitrones for the treatment and prevention of a cerebral stroke or ischaemia | NLN, TXN2, TXN | CA12 1382/4885CA9 1766/4885F11 786/4885 |
| US-20260068882-A1 | ARTHROPOD CONTROLLING COMPOSITION | CNOT9, MSL1, MT-CO2 | CA12 1643/4885CA9 115/4885F11 1213/4885 |
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ATP4B | CA12 4622/4885CA9 2996/4885F11 3921/4885 |
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | CA12 1648/4885CA9 1118/4885F11 1446/4885 |
| US-20240374583-A1 | USE OF MORPHINAN DERIVATIVES FOR TREATMENT OF OPIOID DELTA RECEPTOR AGONIST-RELATED DISEASE | OPRD1, OPRM1, OPRK1 | CA12 4504/4885CA9 4836/4885F11 3636/4885 |
| US-12109209-B2 | Use of morphinan derivatives for treatment of opioid delta receptor agonist-related disease | OPRD1, OPRM1, OPRK1 | CA12 4504/4885CA9 4836/4885F11 3636/4885 |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, ENTPD5, NUDT14 | CA12 4805/4885CA9 4823/4885F11 2981/4885 |
| US-20110112069-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, PURB, NUDT14 | CA12 4773/4885CA9 4787/4885F11 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.